Skip to main content
Premium Trial:

Request an Annual Quote

Ivan Richards

Premium

Sirna Therapeutics said this week that it has appointed Ivan Richards as senior director of pharmacology.

Richards joins Sirna from Pfizer, where he was responsible for preclinical drug discovery activities, including pharmacology, drug metabolism, and toxicology. He received a PhD in pharmacology from the Royal College of Surgeons and has published numerous scientific papers, said Sirna.

“As Sirna moves forward in selecting specific lead RNAi compounds, Ivan’s valuable drug discovery and development experience will help drive the advancement of these product candidates toward clinical trials,” Sirna president and CEO Howard Robin in a statement.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.